Target intelligence / Profile preview

Eukaryotic translation initiation factor 4E family member 1B (EIF4E1B)

Target
EIF4E1B
Molecular classification
Translation initiation factor, Cap-binding protein, RNA-binding protein
01

Overview

EIF4E1B is a member of the eukaryotic translation initiation factor 4E (eIF4E) family, distinguished by its germ cell-specific expression and role in regulating translation of maternal mRNAs during oogenesis and early embryogenesis[2][3][7]. EIF4E1B binds the 5’ cap of mRNAs with lower affinity than canonical eIF4E, and instead of interacting with eIF4G, associates with the CPEB1 repressor complex and 4E-Transporter to modulate the timing and subset of maternal mRNA translation critical for chromatin accessibility and early zygotic gene activation[2][3]. Structure-function analyses show EIF4E1B shares the core fold and many key cap-binding residues with eIF4E, but has distinct N-terminal and loop regions, altering its biochemical properties and binding partners. Its function is limited primarily to germ cells, unlike the broadly expressed canonical eIF4E, and it has not been directly linked to therapeutic targeting or human disease outside of developmental biology research[2][3][7].

Other names
Eukaryotic translation initiation factor 4E type 1BFLJ36951eIF4E1BeIF4E type 1B
02

Mechanism of action

not applicable (No known drugs act directly on EIF4E1B, but translation initiation inhibitors like 4EGI-1 generally act by disrupting eIF4E/eIF4G interactions in related family members[5].)

03

Biological functions

Cap-dependent mRNA bindingRegulation of translation initiationMaternal mRNA translation controlParticipation in translational repression and activation in oocytesInteraction with the CPEB1 complex for translational control of specific maternal transcripts
04

Disease associations

Other (not directly linked to major diseases; its role is primarily in germ cells and early embryogenesis, though broader translation factors are implicated in cancer and other diseases)
05

Safety considerations

Targeting maternal translation in oocytes presents risks of fertility or developmental defects if off-target effects occur, but no specific clinical safety concerns are documented for EIF4E1B[2][3].

Beyond the preview

Go deeper on Eukaryotic translation initiation factor 4E family member 1B (EIF4E1B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eukaryotic translation initiation factor 4E family member 1B (EIF4E1B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call